• This paper introduces TscA to provide atomic invokes for cross-chain DApps. • TscA combines the distributed database TiKV with blockchain technology. • TscA adopts locks to achieve atomic cross-chain operations. • Experimental analyses demonstrate that TscA can effectively achieve atomic cross-chain invokes with an acceptable level of latency. Web 3.0, also known as the next-generation web, aims to create a smarter, more transparent, and user-autonomous Internet of Value through decentralized technologies and intelligent services. Decentralized applications (DApps), as foundational components of the Web 3.0 ecosystem, utilize blockchain and smart contracts to achieve decentralization, transparency, and resistance to tampering. However, DApps deployed on a single blockchain are unable to process invocation requests originating from nodes on other blockchains. Also, while a few DApps support cross-chain interactions, they often do not ensure atomic cross-chain invocations, which are crucial for maintaining consistency and reliability across different blockchain platforms. Moreover, cross-chain users urgently need to verify the trustworthiness of users on other chains, and those with multiple accounts hope that DApps can consolidate the data from these accounts. To address these challenges, this paper proposes TruAtom, a solution comprising the Atomic-Oracle chain and a smart community responsible for coordinating and processing cross-chain transactions. The Atomic-Oracle chain is a relay blockchain system that supports smart contracts. TruAtom enables atomic cross-chain invocations while leveraging the intelligent community on the Atomic-Oracle chain to compute user account reputations across multiple blockchains via Oracle mechanisms. Additionally, this paper proposes an incentive mechanism to enhance the motivation and credibility of member in smart community. Furthermore, this paper validates the security of this scheme through security analysis. Experimental results indicate that TruAtom achieves lower latency and higher success rates for cross-chain invocations compared to AtomCI.
No takes yet. Share an insight, caveat, or question.
A 2025 study studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: